List of Excipients in Branded Drug PALIPERIDONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Patriot Pharmaceuticals LLC	PALIPERIDONE	paliperidone	10147-0952	BUTYLATED HYDROXYTOLUENE
Patriot Pharmaceuticals LLC	PALIPERIDONE	paliperidone	10147-0952	CARNAUBA WAX
Patriot Pharmaceuticals LLC	PALIPERIDONE	paliperidone	10147-0952	CELLULOSE ACETATE
Patriot Pharmaceuticals LLC	PALIPERIDONE	paliperidone	10147-0952	FERROSOFERRIC OXIDE

Generic Drugs Containing PALIPERIDONE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	paliperidone	0378-3978	BUTYLATED HYDROXYTOLUENE
Mylan Pharmaceuticals Inc	paliperidone	0378-3978	CELLULOSE ACETATE
Mylan Pharmaceuticals Inc	paliperidone	0378-3978	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	paliperidone	0378-3978	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in PALIPERIDONE?

# Of NDCs	Excipient
1	ACETONE
1	ALUMINUM OXIDE
15	AMMONIA
8	ANHYDROUS LACTOSE

Last updated: August 8, 2026

ecutive summary: Paliperidone offers two distinct excipient markets: controlled-release oral tablets and long-acting injectable suspensions. The highest-value opportunities are differentiated excipient systems that improve release consistency, reduce tablet manufacturing complexity, stabilize paliperidone palmitate suspensions, or enable lower-volume and less painful injections. Generic competition is more accessible for immediate and extended-release tablets than for long-acting injectables, where particle engineering, suspension rheology, syringeability, device compatibility, and clinical bridging create substantial barriers.

Paliperidone Excipient Strategy and Commercial Opportunities

What formulations contain paliperidone and which excipients are commercially important?

Paliperidone is the active pharmaceutical ingredient in oral extended-release tablets and long-acting injectable products. Its chemical form differs by product:

Product	Active form	Delivery system	Primary excipient opportunity
Invega	Paliperidone	Oral extended-release tablet	Osmotic release, tablet coating, controlled hydration
Invega Sustenna	Paliperidone palmitate	Monthly intramuscular suspension	Particle-size control, suspension stability, injection performance
Invega Trinza	Paliperidone palmitate	Three-month intramuscular suspension	Long-term depot behavior and syringeability
Invega Hafyera	Paliperidone palmitate	Six-month intramuscular suspension	High-concentration depot stability and injection volume reduction

Paliperidone is the major active metabolite of risperidone. The oral product uses a controlled-release tablet architecture, while the injectable products use poorly water-soluble paliperidone palmitate particles suspended in an aqueous vehicle. These mechanisms create different technical and intellectual-property requirements.

What excipients are used in Invega extended-release tablets?

Invega uses an osmotic controlled-release tablet rather than a conventional matrix tablet. The product’s release system uses a semipermeable membrane and a tablet core designed to regulate water ingress and drug delivery. The FDA label identifies excipient classes including polyethylene oxide, povidone, sodium chloride, butylated hydroxytoluene, hypromellose, polyethylene glycol, titanium dioxide, talc, and colorants, depending on tablet strength and presentation.[1]

Why polyethylene oxide matters

Polyethylene oxide is central to the tablet’s controlled-release behavior. It hydrates and forms a viscous gel that controls drug movement through the delivery orifice. Commercially relevant variables include:

• Polymer molecular weight and viscosity grade
• Particle-size distribution
• Compression behavior
• Hydration rate
• Sensitivity to ionic strength
• Drug loading and core geometry
• Membrane permeability
• Laser-drilled or mechanically formed delivery-orifice dimensions

A generic manufacturer cannot treat polyethylene oxide as a simple filler or binder. Substitution with hypromellose, hydroxypropyl cellulose, or a conventional hydrophilic matrix polymer can alter release kinetics and may require substantial formulation and bioequivalence work.

What excipient opportunities exist in oral paliperidone tablets?

The main opportunities are:

1. High-performance polyethylene oxide grades with narrower viscosity variation.
2. Lower-swelling polymers that reduce tablet size.
3. Co-processing systems that improve content uniformity and compression.
4. Protective antioxidants that limit polymer or drug degradation.
5. Film coatings that improve moisture control without changing osmotic release.
6. Excipient systems that reduce sensitivity to manufacturing-scale changes.

A supplier with a validated polymer platform could compete through formulation know-how rather than through commodity excipient pricing. The strongest commercial position would combine polymer supply, application development, dissolution modeling, and scale-up support.

Which excipients are used in paliperidone palmitate injections?

The long-acting injectable products use paliperidone palmitate suspended in an aqueous vehicle. The FDA labels identify polysorbate 20, polyethylene glycol 4000, citric acid monohydrate, dibasic sodium phosphate, sodium hydroxide, and water for injection among the excipients.[2-4]

Excipient	Functional role in paliperidone palmitate injection
Polysorbate 20	Wetting and surface stabilization of drug particles
Polyethylene glycol 4000	Vehicle modification and suspension-supporting function
Citric acid	pH adjustment and buffer component
Dibasic sodium phosphate	Buffer capacity and pH control
Sodium hydroxide	Final pH adjustment
Water for injection	Continuous aqueous phase

The injectable product is technically more difficult than the tablet because product performance depends on the physical properties of the suspended paliperidone palmitate particles. Critical quality attributes include particle-size distribution, crystal form, morphology, surface energy, sedimentation, redispersibility, viscosity, dose uniformity, injection force, and depot persistence.

How should an excipient strategy address paliperidone palmitate suspension stability?

A successful strategy should control the interface between paliperidone palmitate particles and the aqueous vehicle. The formulation must maintain a uniform dose during storage and administration while avoiding excessive viscosity or aggregation.

Surface stabilization

Polysorbate 20 provides wetting and surface stabilization, but surfactant concentration must be controlled. Excess surfactant can increase foaming, interact with packaging surfaces, or affect degradation pathways. Alternatives or complementary systems could include:

• Poloxamers
• Polysorbate 80, subject to compatibility and regulatory justification
• Polyvinyl alcohol
• Low-molecular-weight hydroxypropyl cellulose
• Amino-acid or sugar-based surface modifiers

Any substitution would require comparison of particle wetting, aggregation, injectability, degradation, and local tolerability.

Sedimentation and redispersibility

Suspension performance depends on the relationship between particle size, particle density, vehicle viscosity, and interparticle forces. The commercial target is controlled sedimentation with easy redispersion and no persistent hard cake.

Potential excipient platforms include:

• Low-level polymeric suspending agents
• Optimized polyethylene glycol grades
• Structured vehicles with controlled yield stress
• Surface-active excipient combinations
• Density-matching approaches
• Particle-engineered paliperidone palmitate with reduced aggregation

The preferred system must remain injectable through the intended needle and syringe combination. A formulation that improves sedimentation but materially increases injection force may not be commercially viable.

What excipient technologies could improve Sustenna, Trinza, and Hafyera?

Lower injection volume

The three-month and six-month products create a strong incentive to increase drug concentration while preserving syringeability. Excipient opportunities include:

• More efficient particle packing
• Reduced vehicle viscosity at high solids loading
• Surface modifiers that limit particle agglomeration
• Higher-density suspension systems
• Improved wetting at lower surfactant concentration

Lower injection volume is commercially attractive because it can improve administration logistics and patient acceptance. It is also technically difficult because increasing solids content can raise injection force and accelerate settling.

Improved depot consistency

Paliperidone palmitate hydrolysis and dissolution at the injection site determine prolonged exposure. Excipients that change local wetting, interfacial behavior, or fluid exchange could change the release profile. Development work should focus on maintaining the established pharmacokinetic profile rather than simply maximizing suspension stability.

Reduced injection pain

Pain is affected by injection volume, needle gauge, injection time, vehicle composition, osmolality, pH, particle size, and local tissue response. Commercial opportunities include isotonicity optimization, reduced injection volume, lower injection force, and excipient systems that minimize tissue irritation.

Container-closure compatibility

Long-acting suspensions require compatibility testing with:

• Glass syringes
• Elastomeric plungers
• Needle assemblies
• Lubricants
• Silicone oil
• Secondary packaging
• Extractables and leachables

Polysorbates can interact with surfaces and may contribute to particulate or oxidation concerns under some conditions. A supplier that offers both excipient selection and container-closure compatibility data can create a stronger development position.

What formulation patents protect paliperidone products?

Paliperidone patent protection has historically involved several layers:

1. Composition-of-matter protection for paliperidone or related chemical forms.
2. Controlled-release oral tablet technology.
3. Paliperidone palmitate injectable suspensions.
4. Particle-size, morphology, or crystalline-form limitations.
5. Dosing regimens and loading schedules.
6. Manufacturing processes for producing injectable particles.
7. Device or administration configurations.

The commercially relevant protection for excipient suppliers is usually formulation, process, and manufacturing IP rather than the basic identity of an excipient. A patent may claim a combination of paliperidone palmitate, surfactant, buffer, polymer, particle-size range, and concentration. It may also claim a process that produces a defined particle population.

An excipient supplier should conduct a freedom-to-operate review across U.S., European, Japanese, and other major markets before commercializing a paliperidone-specific system. The review should cover claims directed to:

• Specific surfactant concentrations
• Polyethylene glycol molecular-weight ranges
• Particle-size distributions
• Crystalline forms
• Wet-milling or microcrystallization
• Suspension concentration
• Injection volume
• Dosing intervals
• Combination excipient systems

What is the FDA regulatory status of paliperidone products?

Paliperidone products are approved small-molecule drugs. They are not biologics and do not use the biosimilar pathway.

Regulatory issue	Oral extended-release tablet	Long-acting injectable
FDA pathway for generic competition	Abbreviated New Drug Application	Complex ANDA or other applicable abbreviated pathway
Primary equivalence concern	Pharmacokinetic and release-profile equivalence	Pharmaceutical equivalence, particle attributes, suspension performance, pharmacokinetics
Device dependence	Moderate	High
Excipient substitution risk	Release-profile risk	Physical stability, injection, and local tolerability risk
Clinical bridging burden	Lower than injectable	Higher
Biosimilar pathway	Not applicable	Not applicable

FDA’s product-specific guidance and ANDA requirements are particularly important for complex drug products. For oral extended-release systems, dissolution profiles across multiple conditions are critical. For long-acting injectables, generic developers must address particle characterization, dose uniformity, rheology, injection performance, and comparative pharmacokinetics.[5]

When does paliperidone lose exclusivity, and how does that affect excipient opportunities?

Exclusivity and patent expiry should be evaluated separately. FDA regulatory exclusivity is distinct from patent protection, and the relevant dates may differ by product, strength, formulation, and listed patent.

The Orange Book identifies patents and regulatory exclusivity associated with approved drug products.[6] For paliperidone, the commercially relevant distinction is between:

• Oral extended-release products, where generic entry is more mature and technically familiar.
• Monthly injectable products, where complex formulation and manufacturing requirements create a higher entry barrier.
• Three-month and six-month products, where formulation similarity, dose conversion, and long-acting pharmacokinetic behavior increase development complexity.

Paragraph IV challenges

A Paragraph IV applicant may challenge listed patents by asserting that a patent is invalid, unenforceable, or not infringed. For excipient strategy, the practical question is whether the proposed formulation can avoid claims covering:

• The specific controlled-release architecture
• Paliperidone palmitate particle attributes
• Suspension composition
• Dosing regimen
• Manufacturing process
• Administration method

A non-infringing excipient system can improve launch flexibility, but it cannot eliminate risk if the relevant patent claims are directed to the active ingredient, particle form, or dosing method.

Which companies are positioned in paliperidone excipient and generic competition?

The reference products are associated with Janssen Pharmaceuticals, a Johnson & Johnson company. Competitive activity can arise from:

• Generic pharmaceutical manufacturers developing oral extended-release tablets
• Complex generic developers targeting paliperidone palmitate injections
• Contract development and manufacturing organizations with sterile suspension capabilities
• Excipient manufacturers supplying polyethylene oxide, surfactants, polymers, buffers, and coating systems
• Drug-delivery companies developing depot or particulate platforms

Likely excipient suppliers include manufacturers of pharmaceutical-grade polyethylene oxide, povidone, hypromellose, polysorbates, poloxamers, polyethylene glycol, and coating polymers. Competitive differentiation will depend on regulatory files, lot-to-lot consistency, impurity control, and technical support rather than on ingredient availability alone.

How strong is the patent estate for paliperidone formulations?

The estate is strongest where formulation claims are linked to measurable technical characteristics. Claims covering a defined particle-size range, crystalline form, release profile, concentration, or manufacturing process are generally more relevant to injectable competition than broad claims to conventional excipients.

A formulation patent’s practical strength depends on:

• Whether the claim requires a narrow or broad excipient range
• Whether the limitation is easy to design around
• Whether the claimed attribute can be measured reliably
• Whether the attribute is necessary for clinical performance
• Whether the patent covers the manufacturing process
• Whether the patent is listed in the Orange Book
• Whether the claim reaches commercial-scale production

For excipient companies, the strongest defensible position is a platform patent covering a specific paliperidone formulation, supported by comparative data showing improved stability, reduced injection force, or equivalent pharmacokinetics.

What generic launch risks exist for paliperidone?

Oral tablet launch risks

The primary risks are:

• Failure to match the reference release profile
• Dose dumping under altered pH or mechanical stress
• Polymer variability
• Inadequate content uniformity
• Manufacturing-scale changes
• Orange Book patent litigation
• Difficulty reproducing the controlled-release tablet architecture

Injectable launch risks

The injectable risks are more extensive:

• Particle-size drift during scale-up
• Aggregation during shipping
• Poor redispersibility
• Excessive injection force
• Needle clogging
• Inconsistent dose delivery
• Extractables or leachables
• Local tolerability differences
• Failure to match pharmacokinetic exposure
• Patent claims directed to particle attributes or dosing

These risks make the injectable market more suitable for companies with sterile manufacturing, particle-engineering, analytical, and clinical capabilities.

What commercial opportunities are most attractive?

The best opportunities are differentiated systems with a measurable product benefit.

Opportunity	Commercial attractiveness	Main barrier
Polyethylene oxide supply for oral generics	High volume, moderate margin	Commodity competition and performance qualification
Co-processed oral excipient system	High	Need to match osmotic release behavior
Paliperidone palmitate suspension stabilizer	High value, lower volume	Injectable regulatory and compatibility data
Low-force injection formulation	High	Clinical and device comparability
Reduced-volume high-concentration depot	Very high	Particle packing, viscosity, and PK control
Container-closure compatibility package	Moderate to high	Requires integrated testing
Manufacturing process for paliperidone particles	High	Process IP and scale-up complexity
Excipient intellectual-property licensing	High strategic value	Freedom-to-operate and exclusivity requirements

Licensing opportunities are most credible where a company owns validated data, regulatory documentation, and platform IP. A basic excipient supply agreement is less defensible than a package that includes formulation know-how, analytical methods, process parameters, and regulatory support.

How should companies prioritize paliperidone excipient development?

A practical development sequence is:

1. Select the target product: oral tablet, monthly depot, three-month depot, or six-month depot.
2. Map Orange Book patents and formulation claims.
3. Define critical quality attributes and target product profiles.
4. Screen excipient combinations using design-of-experiments methods.
5. Measure particle size, morphology, sedimentation, redispersibility, viscosity, injection force, and degradation.
6. Conduct container-closure compatibility studies.
7. Establish a scale-up process before making patent or licensing commitments.
8. Generate comparative dissolution or pharmacokinetic data.
9. Build a regulatory package around pharmaceutical equivalence and product-specific guidance.
10. Protect the formulation and manufacturing process with jurisdiction-specific patents.

The highest-return path is usually a formulation platform that can be adapted across multiple long-acting drugs, with paliperidone used as a lead application. A paliperidone-only excipient product may have attractive margins but a smaller addressable market.

Key takeaways

• Paliperidone has two separate excipient markets: osmotic oral tablets and long-acting injectable suspensions.
• Polyethylene oxide is the key technical excipient in the oral controlled-release system.
• Polysorbate 20, polyethylene glycol 4000, citrate, phosphate, sodium hydroxide, and water form the principal injectable vehicle system.
• Injectable opportunities are more valuable but require stronger particle, sterile manufacturing, device, and regulatory capabilities.
• Reduced injection volume, lower injection force, improved redispersibility, and container-closure compatibility are the clearest commercial targets.
• Paliperidone is a small molecule, so biosimilar risk does not apply.
• Orange Book patents, formulation claims, particle attributes, manufacturing processes, and dosing-method patents must be analyzed together.
• The strongest licensing opportunity combines excipient supply with formulation data, process know-how, and regulatory support.

FAQs

Can conventional matrix-tablet excipients replace polyethylene oxide in paliperidone extended-release tablets?

They can be evaluated, but substitution may change hydration, osmotic pressure, membrane behavior, and drug-release kinetics. A conventional hypromellose matrix may not reproduce the reference product’s release mechanism.

Is paliperidone palmitate suitable for a ready-to-use prefilled syringe?

Potentially, but the suspension must maintain dose uniformity, syringeability, stability, and redispersibility throughout shelf life. Syringe materials, lubricants, needle dimensions, and injection force require separate qualification.

What excipient property most affects long-acting paliperidone injection performance?

The most influential properties are particle wetting, interparticle aggregation, vehicle viscosity, and the resulting sedimentation and redispersibility profile. No single excipient property determines performance independently.

Can a new excipient formulation obtain independent patent protection after core paliperidone patents expire?

Yes. A formulation may be patentable if it provides a novel and non-obvious combination of excipients, particle attributes, release behavior, stability, manufacturing process, or administration performance.

Are paliperidone injectable products easier to develop than biologic depot products?

They avoid biologic-specific regulatory issues, but they remain complex drug products. Particle engineering, long-acting pharmacokinetics, sterile suspension manufacturing, and injection-device compatibility can create development barriers comparable to other complex generics.

References

1. U.S. Food and Drug Administration. (2023). Invega (paliperidone) extended-release tablets: Prescribing information. Janssen Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2023). Invega Sustenna (paliperidone palmitate) extended-release injectable suspension: Prescribing information. Janssen Pharmaceuticals, Inc.

3. U.S. Food and Drug Administration. (2023). Invega Trinza (paliperidone palmitate) extended-release injectable suspension: Prescribing information. Janssen Pharmaceuticals, Inc.

4. U.S. Food and Drug Administration. (2023). Invega Hafyera (paliperidone palmitate) extended-release injectable suspension: Prescribing information. Janssen Pharmaceuticals, Inc.

5. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.